NG
LGND icon

Norden Group’s Ligand Pharmaceuticals LGND Stock Holding History

Norden Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$564K Buy
1,783
+524
+42% +$123K 0.05% 344
2026
Q1 		$251K Sell
1,259
-62
-5% -$12.3K 0.02% 515
2025
Q4 		$250K Sell
1,321
-774
-37% -$149K 0.02% 526
2025
Q3 		$371K Buy
+2,095
New +$311K 0.04% 414

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norden Group's LGND Position: Q2 2026 in Review

Norden Group increased its Ligand Pharmaceuticals (LGND) stake by 42% in Q2 2026, buying an estimated $123K and bringing the position to 1,783 shares worth $564K. The position accounts for 0.05% of the portfolio, ranked #344.

Norden Group first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Norden Group held 1,783 shares of Ligand Pharmaceuticals worth $564K as of Q2 2026.
  • Norden Group bought 524 Ligand Pharmaceuticals shares in Q2 2026, an estimated $123K.
  • Ligand Pharmaceuticals made up 0.05% of Norden Group's portfolio in Q2 2026, its #344 holding.
  • Norden Group first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Norden Group's 13F filing for Q2 2026, filed 29 Jul 2026.